First-line late non-scaly NSCLC! Application for listing of reilly Pearl monoanti-new indication was accepted

The sNDA for non-scale NSCLC is based on the results of a Phase 3 clinical trial, which is Bacaan ® combined with permeitus and the platinum chemotherapy drug (carped or cisplatin) chosen by the researchers, for the treatment of patients with untreated and non-scaly NSCLC patients with either EGFR mutation or ALK translocation or non-scaleNSCLC (clinicals.gov registration number: NC03663205)In the trial, a total of 334 patients were randomly treated with Bacaan ® combination chemotherapy or chemotherapy only at a ratio of 2:1As reported in April 2020, the trial, assessed by the Independent Review Board (IRC) in the planned mid-term analysis, reached the primary endpoint, i.e., a statistically significant improvement in progression-free survival (PFS)The safety data of the combination of Baccarat ® combined with the combination of permeycenic and platinum chemotherapy drugs matched the known risks in each group and no new safety warnings appearedThe full clinical trial data will be presented at a recent academic conference.